Sigma-Aldrich announced the release of over 2,300 antibody additions to its Prestige Antibodies powered by Atlas Antibodies product line, bringing the total number of highly validated antibodies to over 6,100. Developed by the Human Proteome Resource, these antibodies are available to customers immediately through an exclusive partnership between Sigma-Aldrich and Atlas Antibodies. Prestige Antibodies can provide significant time and cost savings for researchers because they are optimized on a single protocol, resulting in efficient and effective applications.
This addition to the Prestige Antibodies product line is a step toward the Human Proteome Resource’s goal to develop at least one antibody to all 22,000 non-redundant human proteins by 2015.
“With this latest addition to the Prestige Antibodies line, Sigma-Aldrich has significantly expanded our antibody offerings, the latest step in our long-term plan to lead the industry in high-quality antibody content,” said Dr. David Smoller, President of Sigma-Aldrich’s Research Biotech Business Unit. “Our highly validated Prestige Antibodies are ideal for a number of applications, and with our unique online tools we help scientists figure out how to best incorporate them into prospective experiments.”
Prestige Antibodies are supported by the publicly available data of the Human Protein Atlas (HPA), part of HUPO’s Human Antibody Initiative. Multiple quality assurance testing steps ensure that Prestige Antibodies are highly specific to their targets. Each Prestige Antibody is also associated with over 500 tissue immunohistochemistry (IHC) images, over 100 cell/line immunocytochemistry (ICC) images, immunofluorescence (IF) and western blotting (WB) data, all publicly accessible via the Human Protein Atlas.
In August 2008, Sigma-Aldrich added over 2,000 Prestige Antibodies to the existing antibody product line. The rapid expansion of the Sigma-Aldrich Prestige Antibodies gives an increasing number of scientists the ability to save resources and facilitate high-throughput applications in proteomics and cell biology research.
Date: June 23, 2009
Source: Sigma-Aldrich
Filed Under: Drug Discovery
